Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study
Objective. To compare the clinical efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) plus intravenous chemotherapy of paclitaxel with or without sintilimab in peritoneal metastasis of gastric cancer. Methods. A total of 120 patients assessed for eligibility with peritoneal metastasis of...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology 2022-02, Vol.2022, p.3054485-6 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6 |
|---|---|
| container_issue | |
| container_start_page | 3054485 |
| container_title | Journal of oncology |
| container_volume | 2022 |
| creator | Zhang, Zao Ning, Mei-Ying Han, Dong Li, Li Li, Zhuang-Zhuang |
| description | Objective. To compare the clinical efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) plus intravenous chemotherapy of paclitaxel with or without sintilimab in peritoneal metastasis of gastric cancer. Methods. A total of 120 patients assessed for eligibility with peritoneal metastasis of gastric cancer treated in the oncology department of our hospital from January 2019 to June 2020 were recruited. They were concurrently randomly assigned in a 1 : 1 ratio to receive HIPEC plus sintilimab-paclitaxel intravenous chemotherapy (study group) or plus paclitaxel intravenous chemotherapy only (control group). Results. The objective remission rate (ORR) of ascites in the study group was significantly higher than that in the control group. Subgroup analysis showed that an age ≤60 years or well-differentiated tumors were associated with better objective remission. After treatment, significantly higher Karnofsky Performance Status (KPS) scores were observed in the study group versus those of the control group. Adverse events reported were comparable between groups. The study group obtained longer 12-month progression-free survival (PFS) and overall survival (OS) than those of the control group. Conclusion. On top of HIPEC, intravenous chemotherapy with sintilimab and paclitaxel constitute an effective alternative for patients with peritoneal metastasis of gastric cancer to enhance ascites remission, ameliorate the quality of life, and prolong survival, versus with paclitaxel alone. |
| doi_str_mv | 10.1155/2022/3054485 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8888085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A697672477</galeid><sourcerecordid>A697672477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-cb21a649e4dc1dcca891d40af020ba0a106722d90440b8c0850576c355be3a2f3</originalsourceid><addsrcrecordid>eNp9kk9v1DAQxSMEon_gxhlZ4oIES23HdpIekFYraCtVAqlwtiaO07hy7OA4W_aT9OvikKW0HPBlbM1Pb-ZZL8teEfyBEM5PKKb0JMecsZI_yQ6JKItVyTh--uB-kB2N4w3GguFKPM8Ock4ZJaU4zO7Od4MOsdOhNwpduBggvU30ToNFm073fm7CsEODncaF2Grn0_1R17foKyhrIvzUFt2a2CEfflc_RXRlXDTW9FAj49AZjDGkcRtwSodTtEYb3w8QIJqtRldxanYvsmct2FG_3Nfj7PvnT98256vLL2cXm_XlSrE8jytVUwKCVZo1ijRKQVmRhmFoMcU1YCBYFJQ2FWYM16XCJce8ECrnvNY50DY_zj4uusNU97pRevZn5RDSrmEnPRj5uONMJ6_9VpbpJLkk8HYvEPyPSY9R9mZU2lpwOn2SpCIXhPEiLxL65h_0xk_BJXsLxQkvy7_UNVgtjWt9mqtmUbkWVZH8sGLWer9QKvhxDLq9X5lgOedCzrmQ-1wk_PVDm_fwnyAk4N0CdMY1cGv-L_cLL7nCTQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2636151588</pqid></control><display><type>article</type><title>Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study</title><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Zhang, Zao ; Ning, Mei-Ying ; Han, Dong ; Li, Li ; Li, Zhuang-Zhuang</creator><contributor>Yuan, Qin</contributor><creatorcontrib>Zhang, Zao ; Ning, Mei-Ying ; Han, Dong ; Li, Li ; Li, Zhuang-Zhuang ; Yuan, Qin</creatorcontrib><description>Objective. To compare the clinical efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) plus intravenous chemotherapy of paclitaxel with or without sintilimab in peritoneal metastasis of gastric cancer. Methods. A total of 120 patients assessed for eligibility with peritoneal metastasis of gastric cancer treated in the oncology department of our hospital from January 2019 to June 2020 were recruited. They were concurrently randomly assigned in a 1 : 1 ratio to receive HIPEC plus sintilimab-paclitaxel intravenous chemotherapy (study group) or plus paclitaxel intravenous chemotherapy only (control group). Results. The objective remission rate (ORR) of ascites in the study group was significantly higher than that in the control group. Subgroup analysis showed that an age ≤60 years or well-differentiated tumors were associated with better objective remission. After treatment, significantly higher Karnofsky Performance Status (KPS) scores were observed in the study group versus those of the control group. Adverse events reported were comparable between groups. The study group obtained longer 12-month progression-free survival (PFS) and overall survival (OS) than those of the control group. Conclusion. On top of HIPEC, intravenous chemotherapy with sintilimab and paclitaxel constitute an effective alternative for patients with peritoneal metastasis of gastric cancer to enhance ascites remission, ameliorate the quality of life, and prolong survival, versus with paclitaxel alone.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>DOI: 10.1155/2022/3054485</identifier><identifier>PMID: 35242186</identifier><language>eng</language><publisher>Egypt: Hindawi</publisher><subject>Abdomen ; Activities of daily living ; Ascites ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Comparative analysis ; Gastric cancer ; Hospitalization ; Medical prognosis ; Metastasis ; Oncology, Experimental ; Paclitaxel ; Pharmaceutical industry ; Quality of life ; Remission (Medicine) ; Stomach cancer ; Tumors</subject><ispartof>Journal of oncology, 2022-02, Vol.2022, p.3054485-6</ispartof><rights>Copyright © 2022 Zao Zhang et al.</rights><rights>COPYRIGHT 2022 John Wiley & Sons, Inc.</rights><rights>Copyright © 2022 Zao Zhang et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022 Zao Zhang et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c433t-cb21a649e4dc1dcca891d40af020ba0a106722d90440b8c0850576c355be3a2f3</cites><orcidid>0000-0003-1145-1889</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888085/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888085/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35242186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Yuan, Qin</contributor><creatorcontrib>Zhang, Zao</creatorcontrib><creatorcontrib>Ning, Mei-Ying</creatorcontrib><creatorcontrib>Han, Dong</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Li, Zhuang-Zhuang</creatorcontrib><title>Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study</title><title>Journal of oncology</title><addtitle>J Oncol</addtitle><description>Objective. To compare the clinical efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) plus intravenous chemotherapy of paclitaxel with or without sintilimab in peritoneal metastasis of gastric cancer. Methods. A total of 120 patients assessed for eligibility with peritoneal metastasis of gastric cancer treated in the oncology department of our hospital from January 2019 to June 2020 were recruited. They were concurrently randomly assigned in a 1 : 1 ratio to receive HIPEC plus sintilimab-paclitaxel intravenous chemotherapy (study group) or plus paclitaxel intravenous chemotherapy only (control group). Results. The objective remission rate (ORR) of ascites in the study group was significantly higher than that in the control group. Subgroup analysis showed that an age ≤60 years or well-differentiated tumors were associated with better objective remission. After treatment, significantly higher Karnofsky Performance Status (KPS) scores were observed in the study group versus those of the control group. Adverse events reported were comparable between groups. The study group obtained longer 12-month progression-free survival (PFS) and overall survival (OS) than those of the control group. Conclusion. On top of HIPEC, intravenous chemotherapy with sintilimab and paclitaxel constitute an effective alternative for patients with peritoneal metastasis of gastric cancer to enhance ascites remission, ameliorate the quality of life, and prolong survival, versus with paclitaxel alone.</description><subject>Abdomen</subject><subject>Activities of daily living</subject><subject>Ascites</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Comparative analysis</subject><subject>Gastric cancer</subject><subject>Hospitalization</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Oncology, Experimental</subject><subject>Paclitaxel</subject><subject>Pharmaceutical industry</subject><subject>Quality of life</subject><subject>Remission (Medicine)</subject><subject>Stomach cancer</subject><subject>Tumors</subject><issn>1687-8450</issn><issn>1687-8450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kk9v1DAQxSMEon_gxhlZ4oIES23HdpIekFYraCtVAqlwtiaO07hy7OA4W_aT9OvikKW0HPBlbM1Pb-ZZL8teEfyBEM5PKKb0JMecsZI_yQ6JKItVyTh--uB-kB2N4w3GguFKPM8Ock4ZJaU4zO7Od4MOsdOhNwpduBggvU30ToNFm073fm7CsEODncaF2Grn0_1R17foKyhrIvzUFt2a2CEfflc_RXRlXDTW9FAj49AZjDGkcRtwSodTtEYb3w8QIJqtRldxanYvsmct2FG_3Nfj7PvnT98256vLL2cXm_XlSrE8jytVUwKCVZo1ijRKQVmRhmFoMcU1YCBYFJQ2FWYM16XCJce8ECrnvNY50DY_zj4uusNU97pRevZn5RDSrmEnPRj5uONMJ6_9VpbpJLkk8HYvEPyPSY9R9mZU2lpwOn2SpCIXhPEiLxL65h_0xk_BJXsLxQkvy7_UNVgtjWt9mqtmUbkWVZH8sGLWer9QKvhxDLq9X5lgOedCzrmQ-1wk_PVDm_fwnyAk4N0CdMY1cGv-L_cLL7nCTQ</recordid><startdate>20220222</startdate><enddate>20220222</enddate><creator>Zhang, Zao</creator><creator>Ning, Mei-Ying</creator><creator>Han, Dong</creator><creator>Li, Li</creator><creator>Li, Zhuang-Zhuang</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1145-1889</orcidid></search><sort><creationdate>20220222</creationdate><title>Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study</title><author>Zhang, Zao ; Ning, Mei-Ying ; Han, Dong ; Li, Li ; Li, Zhuang-Zhuang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-cb21a649e4dc1dcca891d40af020ba0a106722d90440b8c0850576c355be3a2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Abdomen</topic><topic>Activities of daily living</topic><topic>Ascites</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Comparative analysis</topic><topic>Gastric cancer</topic><topic>Hospitalization</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Oncology, Experimental</topic><topic>Paclitaxel</topic><topic>Pharmaceutical industry</topic><topic>Quality of life</topic><topic>Remission (Medicine)</topic><topic>Stomach cancer</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Zao</creatorcontrib><creatorcontrib>Ning, Mei-Ying</creatorcontrib><creatorcontrib>Han, Dong</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Li, Zhuang-Zhuang</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Zao</au><au>Ning, Mei-Ying</au><au>Han, Dong</au><au>Li, Li</au><au>Li, Zhuang-Zhuang</au><au>Yuan, Qin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study</atitle><jtitle>Journal of oncology</jtitle><addtitle>J Oncol</addtitle><date>2022-02-22</date><risdate>2022</risdate><volume>2022</volume><spage>3054485</spage><epage>6</epage><pages>3054485-6</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><abstract>Objective. To compare the clinical efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) plus intravenous chemotherapy of paclitaxel with or without sintilimab in peritoneal metastasis of gastric cancer. Methods. A total of 120 patients assessed for eligibility with peritoneal metastasis of gastric cancer treated in the oncology department of our hospital from January 2019 to June 2020 were recruited. They were concurrently randomly assigned in a 1 : 1 ratio to receive HIPEC plus sintilimab-paclitaxel intravenous chemotherapy (study group) or plus paclitaxel intravenous chemotherapy only (control group). Results. The objective remission rate (ORR) of ascites in the study group was significantly higher than that in the control group. Subgroup analysis showed that an age ≤60 years or well-differentiated tumors were associated with better objective remission. After treatment, significantly higher Karnofsky Performance Status (KPS) scores were observed in the study group versus those of the control group. Adverse events reported were comparable between groups. The study group obtained longer 12-month progression-free survival (PFS) and overall survival (OS) than those of the control group. Conclusion. On top of HIPEC, intravenous chemotherapy with sintilimab and paclitaxel constitute an effective alternative for patients with peritoneal metastasis of gastric cancer to enhance ascites remission, ameliorate the quality of life, and prolong survival, versus with paclitaxel alone.</abstract><cop>Egypt</cop><pub>Hindawi</pub><pmid>35242186</pmid><doi>10.1155/2022/3054485</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1145-1889</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1687-8450 |
| ispartof | Journal of oncology, 2022-02, Vol.2022, p.3054485-6 |
| issn | 1687-8450 1687-8450 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8888085 |
| source | Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Abdomen Activities of daily living Ascites Cancer Cancer therapies Care and treatment Chemotherapy Comparative analysis Gastric cancer Hospitalization Medical prognosis Metastasis Oncology, Experimental Paclitaxel Pharmaceutical industry Quality of life Remission (Medicine) Stomach cancer Tumors |
| title | Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A38%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperthermic%20Intraperitoneal%20Chemotherapy%20plus%20Intravenous%20Chemotherapy%20of%20Paclitaxel%20with%20or%20without%20Sintilimab%20in%20Gastric%20Cancer:%20A%20Comparative%20Study&rft.jtitle=Journal%20of%20oncology&rft.au=Zhang,%20Zao&rft.date=2022-02-22&rft.volume=2022&rft.spage=3054485&rft.epage=6&rft.pages=3054485-6&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2022/3054485&rft_dat=%3Cgale_pubme%3EA697672477%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2636151588&rft_id=info:pmid/35242186&rft_galeid=A697672477&rfr_iscdi=true |